Immunome (NASDAQ:IMNM) Stock Price Up 9.8% – What’s Next?

Immunome, Inc. (NASDAQ:IMNM)’s stock price rose 9.8% on Friday . The stock traded as high as $6.76 and last traded at $6.81. Approximately 314,708 shares traded hands during trading, a decline of 65% from the average daily volume of 892,587 shares. The stock had previously closed at $6.20.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the stock. Lake Street Capital initiated coverage on shares of Immunome in a research report on Wednesday, April 2nd. They set a “buy” rating and a $23.00 price objective on the stock. Guggenheim cut their price target on shares of Immunome from $35.00 to $25.00 and set a “buy” rating on the stock in a report on Thursday, March 20th. Wedbush restated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Thursday, March 20th. Lifesci Capital started coverage on Immunome in a research report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price objective on the stock. Finally, Stephens reissued an “overweight” rating and issued a $30.00 target price on shares of Immunome in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Immunome has an average rating of “Buy” and an average target price of $25.14.

Immunome Trading Up 14.5 %

The business’s 50 day simple moving average is $8.56 and its two-hundred day simple moving average is $10.60. The firm has a market capitalization of $617.35 million, a PE ratio of -0.88 and a beta of 2.05.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.84) EPS for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.16). The firm had revenue of $2.74 million for the quarter, compared to analysts’ expectations of $3.07 million. Immunome had a negative net margin of 3,014.59% and a negative return on equity of 48.63%. As a group, equities research analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current year.

Insider Transactions at Immunome

In related news, CEO Clay B. Siegall bought 150,000 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were bought at an average cost of $7.75 per share, with a total value of $1,162,500.00. Following the acquisition, the chief executive officer now owns 669,636 shares in the company, valued at $5,189,679. This trade represents a 28.87 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jean Jacques Bienaime purchased 7,000 shares of the business’s stock in a transaction on Monday, March 24th. The shares were bought at an average cost of $8.21 per share, with a total value of $57,470.00. Following the acquisition, the director now directly owns 23,615 shares of the company’s stock, valued at $193,879.15. This trade represents a 42.13 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 306,400 shares of company stock worth $2,322,995 in the last quarter. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMNM. Geode Capital Management LLC raised its position in shares of Immunome by 13.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,207,455 shares of the company’s stock valued at $17,657,000 after purchasing an additional 144,557 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Immunome by 3.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 457,252 shares of the company’s stock valued at $4,856,000 after acquiring an additional 14,775 shares during the period. Magnus Financial Group LLC lifted its position in shares of Immunome by 107.8% in the fourth quarter. Magnus Financial Group LLC now owns 53,536 shares of the company’s stock valued at $569,000 after acquiring an additional 27,777 shares in the last quarter. Barclays PLC lifted its position in shares of Immunome by 125.9% in the third quarter. Barclays PLC now owns 105,886 shares of the company’s stock valued at $1,547,000 after acquiring an additional 59,016 shares in the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of Immunome by 137.1% in the third quarter. Wellington Management Group LLP now owns 140,690 shares of the company’s stock worth $2,057,000 after acquiring an additional 81,354 shares during the period. Institutional investors own 44.58% of the company’s stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.